USA hCG reference service, 10-year report

Cole, Laurence A.; Laidler, Laura; Muller, Carolyn Y.

doi:10.1016/j.clinbiochem.2010.05.006

Cited by 27 publications

(29 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 A 10-year report of the USA hCG Reference Service identified 83 of 565 recorded consulting cases to be false positives. 2 In 62 of these 83 cases, patients underwent unnecessary chemotherapy or hysterectomy, which led to lawsuits. 2 The We performed these procedures and concluded that there was neither evidence of assay interference nor any other laboratory error in this case.…”

Section: Phantom Hcgmentioning

confidence: 99%

“…2 In 62 of these 83 cases, patients underwent unnecessary chemotherapy or hysterectomy, which led to lawsuits. 2 The We performed these procedures and concluded that there was neither evidence of assay interference nor any other laboratory error in this case. Additionally, the serum can be tested with a different commercial hCG immunoassay to see if this results in a substantially discrepant level.…”

Section: Phantom Hcgmentioning

confidence: 99%

“…8,9 The USA hCG Reference Service recommends using the cutoff of free β-hCG greater than 40% of total hCG to identify cancers and cases of placental site troph oblastic disease. 2 Serum hyperglycosylated hCG greater than 30% of total hCG is suggested to distinguish aggressive gestational trophoblastic disease and minimally invasive gestational trophoblastic disease, which is generally chemorefractory, with a very slow hCG doubling rate of about two to six weeks. 2 Quiescent gestational trophoblastic disease In the 10-year report of the USA hCG Reference Service, 168 of the 565 consulting cases had no demonstrated serum hyperglycosylated hCG.…”

Section: Gestational Trophoblastic Diseasementioning

confidence: 99%

“…2 Serum hyperglycosylated hCG greater than 30% of total hCG is suggested to distinguish aggressive gestational trophoblastic disease and minimally invasive gestational trophoblastic disease, which is generally chemorefractory, with a very slow hCG doubling rate of about two to six weeks. 2 Quiescent gestational trophoblastic disease In the 10-year report of the USA hCG Reference Service, 168 of the 565 consulting cases had no demonstrated serum hyperglycosylated hCG. In these 168 cases, three-month to twoyear plateaus of stable hCG levels were seen, with levels ranging from 1.6 to 212 IU/L.…”

Section: Gestational Trophoblastic Diseasementioning

confidence: 99%

“…[1][2][3][4][5][6] These include new pregnancy, retained products of conception, a false-positive hCG result, pituitary or menopausal hCG, nontrophoblastic cancer and gestational trophoblastic disease.…”

Section: Key Pointsmentioning

confidence: 99%

See 4 more Smart Citations

Persistent mild increase of human chorionic gonadotropin levels in a 31-year-old woman after spontaneous abortion

Chen

Samson

Bentley

et al. 2016

CMAJ

View full text Add to dashboard Cite

show abstract

Section: Phantom Hcgmentioning

confidence: 99%

Section: Phantom Hcgmentioning

confidence: 99%

Section: Gestational Trophoblastic Diseasementioning

confidence: 99%

Section: Gestational Trophoblastic Diseasementioning

confidence: 99%

Section: Key Pointsmentioning

confidence: 99%

See 3 more Smart Citations

Persistent mild increase of human chorionic gonadotropin levels in a 31-year-old woman after spontaneous abortion

Chen

Samson

Bentley

et al. 2016

CMAJ

View full text Add to dashboard Cite

show abstract

From individual proteins to proteomic samples: characterization of O-glycosylation sites in human chorionic gonadotropin and human-plasma proteins

Bai

Zhu

et al. 2015

Anal Bioanal Chem

View full text Add to dashboard Cite

O-glycosylation-site characterization of individual glycoproteins is a major challenge because of the heterogeneity of O-glycan core structures. In proteomic studies, O-glycosylation-site analysis is even more difficult because of the complexity of the sample. In this work, we designed a rapid and convenient workflow for characterizing the O-glycosylation sites of individual proteins and the human-plasma proteome. A mixture of exoglycosidases was used to partially remove O-glycan chains and leave an N-acetylgalacosamine (GalNAc) residue attached to the Ser or Thr residues. The O-glycosylated peptides could then be identified by using liquid chromatography-tandem mass spectrometry (LC-MS-MS) to detect the 203 Da mass increase. Jacalin was used to selectively isolate O-GalNAc glycopeptides before LC-MS-MS analysis, which is optional for individual proteins and necessary for complex human-plasma proteins. Bovine fetuin and human chorionic gonadotropin (hCG) were used to test the analytical workflow. The workflow indicated superior sensitivity by not only covering most previously known O-glycosylation sites but also discovering several novel sites. Using only one drop of blood, a total of 49 O-GalNAc-linked glycopeptides from 36 distinctive glycoproteins in human plasma were identified unambiguously. The approach described herein is simple, sensitive, and global for site analysis of core 1 through core 4 O-glycosylated proteins.

show abstract

Historical, morphological and clinical overview of placental site trophoblastic tumors: from bench to bedside

Santoro

Laganà

Micali

et al. 2016

Arch Gynecol Obstet

View full text Add to dashboard Cite

The lack of uniformity in data collection seen so far has limited full knowledge of PSTT. For this reason, we suggest a model (PSTT model) that collects and unifies PSTT evidence as this would be useful to identify worldwide precise prognostic factors, which are still lacking. When PSTT is diagnosed, the proper procedure seems to be total hysterectomy, with sampling of pelvic lymph nodes and ovarian conservation. For advanced-stage diseases, (stage III and IV) a combination of surgery and polychemotherapy is suggested.

show abstract

USA hCG reference service, 10-year report

Cited by 27 publications

References 25 publications

Persistent mild increase of human chorionic gonadotropin levels in a 31-year-old woman after spontaneous abortion

Persistent mild increase of human chorionic gonadotropin levels in a 31-year-old woman after spontaneous abortion

From individual proteins to proteomic samples: characterization of O-glycosylation sites in human chorionic gonadotropin and human-plasma proteins

Historical, morphological and clinical overview of placental site trophoblastic tumors: from bench to bedside

Contact Info

Product

Resources

About